BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang S, Gao X, Zhang L, Yang E, Li Y, Yu L. The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Curr Oncol 2021;28:1077-93. [PMID: 33652996 DOI: 10.3390/curroncol28020105] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Gupta S, Shukla S. Limitations of Immunotherapy in Cancer. Cureus 2022. [DOI: 10.7759/cureus.30856] [Reference Citation Analysis]
2 Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol 2022;11:38. [PMID: 35725570 DOI: 10.1186/s40164-022-00291-0] [Reference Citation Analysis]
3 Maddineni S, Silberstein JL, Sunwoo JB. Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. J Immunother Cancer 2022;10:e004693. [PMID: 35580928 DOI: 10.1136/jitc-2022-004693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yan J, Yu W, Lu C, Liu C, Wang G, Jiang L, Jiang Z, Qin Z. High ORAI3 expression correlates with good prognosis in human muscle-invasive bladder cancer. Gene 2022;808:145994. [PMID: 34626722 DOI: 10.1016/j.gene.2021.145994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, Koo S, Kwon SP, Moon S, Jung M, Hong J, Go S, Song SY, Choi JH, Hyeon T, Oh YK, Park HH, Kim BS. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Adv Mater 2021;33:e2103258. [PMID: 34510559 DOI: 10.1002/adma.202103258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
6 Hamilton G, Plangger A. The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy. Biologics 2021;15:265-77. [PMID: 34262255 DOI: 10.2147/BTT.S290305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
7 Varudkar N, Oyer JL, Copik A, Parks GD. Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling. J Immunother Cancer 2021;9:e002373. [PMID: 34172515 DOI: 10.1136/jitc-2021-002373] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Kaweme NM, Zhou F. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment. Front Immunol 2021;12:683381. [PMID: 34220833 DOI: 10.3389/fimmu.2021.683381] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Yu J, Wang Q, Zhang X, Guo Z, Cui X. Mechanisms of Neoantigen-Targeted Induction of Pyroptosis and Ferroptosis: From Basic Research to Clinical Applications. Front Oncol 2021;11:685377. [PMID: 34123855 DOI: 10.3389/fonc.2021.685377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]